Bruker (NASDAQ:BRKR) Shares Down 7.1% – Time to Sell?

Bruker Corporation (NASDAQ:BRKR) was down 7.1% on Wednesday . The stock traded as low as $55.08 and last traded at $54.21. 230,821 shares changed hands during trading, a decline of 90% from the average session volume of 2,339,288 shares. The stock had previously closed at $58.37.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BRKR. UBS Group initiated coverage on Bruker in a research note on Wednesday. They issued a “neutral” rating and a $65.00 price objective for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Wolfe Research assumed coverage on shares of Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating for the company. Barclays boosted their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $57.00.

Bruker Price Performance

The firm has a market capitalization of $8.30 billion, a PE ratio of -77.73, a P/E/G ratio of 1.79 and a beta of 1.26. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company has a fifty day moving average price of $58.70 and a two-hundred day moving average price of $49.00.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio is -28.57%.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd grew its stake in shares of Bruker by 5.4% in the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after purchasing an additional 761,258 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in Bruker in the 2nd quarter valued at $570,746,000. California State Teachers Retirement System increased its stake in Bruker by 5,982.2% in the 2nd quarter. California State Teachers Retirement System now owns 7,455,459 shares of the medical research company’s stock valued at $448,670,000 after buying an additional 7,332,880 shares during the period. State Street Corp raised its position in Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after buying an additional 91,706 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.